4 transcripts
NTRA
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
to deliver a more accurate risk assessment across both acute cellular rejection and antibody-mediated rejection, then with donor-derived cell-free DNA
NTRA
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
this launch as a key differentiator for Natera on several fronts. First, the vast majority of other NIPT labs do not offer fetal RhD assessment with only
NTRA
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
between Prospera and endomyocardial biopsy assessed with the molecular microscope.
Reporting an area under the ROC curve of 0.9, you can see
NTRA
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
believe that now is the time to be implementing MRD assessment into routine clinical practice. This is a sentiment we heard a number of times during
- Prev
- 1
- Next